Lexeo Therapeutics (NASDAQ:LXEO) Announces Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Posted by Wayne Rhoads on Mar 25th, 2025

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09, Zacks reports.

Lexeo Therapeutics Stock Performance

Shares of Lexeo Therapeutics stock opened at $4.09 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The firm has a market cap of $135.24 million, a price-to-earnings ratio of -1.29 and a beta of 3.85. Lexeo Therapeutics has a one year low of $2.32 and a one year high of $19.50. The stock’s 50-day moving average is $4.15 and its 200-day moving average is $6.71.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday, January 21st. Leerink Partners dropped their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research report on Monday. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Lexeo Therapeutics has an average rating of “Buy” and a consensus target price of $23.60.

Read Our Latest Research Report on LXEO

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.